Dynavax Technologies Corporation
DVAXDrugs in Pipeline
8
Phase 3 Programs
4
Upcoming Catalysts
1
Next Catalyst
May 29, 2026
14wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
HEPLISAV-B
Chronic Kidney Disease
HEPLISAV
Hepatitis B
Engerix-B
Hepatitis B
Fendrix
End Stage Renal Disease
Amb a 1 Immunostimulatory Oligoribonucleotide Conjugate
Rhinitis, Allergic, Seasonal
Z-1018
Shingles
rF1V-1018
Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis
rF1V vaccine
Plague, Pneumonic
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
HEPLISAV-B | Phase 3 | Chronic Kidney Disease | - |
HEPLISAV | Phase 3 | Hepatitis B | - |
Engerix-B | Phase 3 | Hepatitis B | - |
Fendrix | Phase 3 | End Stage Renal Disease | - |
Amb a 1 Immunostimulatory Oligoribonucleotide Conjugate | Phase 2 | Rhinitis, Allergic, Seasonal | - |
Z-1018 | Phase 2 | Shingles | - |
rF1V-1018 | Phase 2 | Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis | - |
rF1V vaccine | Phase 2 | Plague, Pneumonic | - |